See more : Ocean Star Technology Group Limited (8297.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Athersys, Inc. (ATHX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athersys, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xiamen International Airport Co.,Ltd (600897.SS) Income Statement Analysis – Financial Results
- Endeavour Group Limited (EDV.AX) Income Statement Analysis – Financial Results
- DSV A/S (DSV.CO) Income Statement Analysis – Financial Results
- Lenovo Group Limited (LNVGY) Income Statement Analysis – Financial Results
- Mount Gibson Iron Limited (MTGRF) Income Statement Analysis – Financial Results
Athersys, Inc. (ATHX)
About Athersys, Inc.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 5.51M | 1.43M | 5.52M | 23.74M | 2.84M | 16.24M | 10.30M | 286.00K | 755.00K | 7.38M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -554.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 5.51M | 1.43M | 5.52M | 24.29M | 2.84M | 16.24M | 11.95M | 1.62M | 2.44M | 8.71M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 102.33% | 100.00% | 100.00% | 116.02% | 567.48% | 322.91% | 117.99% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 65.03M | 71.08M | 62.99M | 39.05M | 38.66M | 27.84M | 24.84M | 21.32M | 23.37M | 20.48M | 19.64M | 18.93M | 14.78M | 11.92M | 16.50M | 15.82M | 0.00 | 12.58M | 0.00 | 13.68M |
| General & Administrative | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Other Expenses | 1.42M | 1.43M | 882.00K | 582.00K | 762.00K | 314.00K | 209.00K | -61.00K | 86.00K | 38.00K | -1.17M | 278.00K | 284.00K | 233.00K | 218.00K | 283.00K | 0.00 | 982.00K | 0.00 | 22.19M |
| Operating Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Cost & Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.00K | 85.00K | 203.00K | 375.00K | 1.15M | 1.59M | 0.00 | 317.00K | 0.00 | 644.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 243.00K | 0.00 | 0.00 | 94.00K | 1.26M | 0.00 | 964.00K | 0.00 | 135.00K |
| Depreciation & Amortization | 1.42M | 1.43M | 890.00K | 698.00K | 855.00K | 684.00K | 382.00K | 267.00K | 360.00K | 346.00K | 320.00K | 278.00K | 284.00K | 233.00K | 218.00K | 231.00K | 0.00 | 938.00K | 0.00 | 1.80M |
| EBITDA | -75.59M | -85.63M | -77.44M | -44.79M | -25.42M | -33.33M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -20.82M | -11.23M | -15.62M | -18.91M | -20.82M | -1.51K | -12.50M | 0.00 | -30.83M |
| EBITDA Ratio | -1,419.51% | -1,552.97% | -5,407.96% | -811.85% | -107.11% | -1,172.25% | -95.15% | -171.64% | -12,322.73% | -2,355.89% | -245.05% | -130.04% | -124.82% | -706.62% | -609.44% | -677.70% | 0.00% | -347.72% | 0.00% | -1,432.57% |
| Operating Income | -77.01M | -87.06M | -78.33M | -45.49M | -25.05M | -33.28M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -13.78M | -11.51M | -15.62M | -19.09M | -20.82M | -1.51K | -13.97M | 0.00 | -34.78M |
| Operating Income Ratio | -1,446.18% | -1,578.85% | -5,470.11% | -824.51% | -105.51% | -1,170.70% | -92.54% | -166.74% | -10,144.06% | -3,239.34% | -216.82% | -133.22% | -128.77% | -723.25% | -614.88% | -638.50% | 0.00% | -388.49% | 0.00% | -1,616.36% |
| Total Other Income/Expenses | 4.48M | 103.00K | -433.00K | 906.00K | 762.00K | 1.04M | -348.00K | 711.00K | 6.68M | -6.29M | 1.27M | 34.00K | 134.00K | 249.00K | 1.10M | -3.57M | -52.00K | -233.00K | 0.00 | -1.08M |
| Income Before Tax | -72.53M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.37M | -16.46M | -22.34M | -30.74M | -14.74M | -24.39M | -11.38M | -17.99M | -17.99M | -24.39M | 0.00 | -14.20M | 0.00 | -35.86M |
| Income Before Tax Ratio | -1,362.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.68% | -159.84% | -7,809.44% | -4,071.92% | -199.66% | -235.74% | -127.27% | -833.35% | -579.45% | -748.01% | 0.00% | -394.97% | 0.00% | -1,666.36% |
| Income Tax Expense | -4.47M | 0.00 | 0.00 | 0.00 | 762.00K | -728.00K | -37.00K | -38.00K | -253.00K | 6.32M | -2.44M | -34.00K | -134.00K | -249.00K | -1.10M | -1.84M | 1.51K | 924.00K | 0.00 | -547.00K |
| Net Income | -68.06M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.34M | -16.42M | -22.08M | -30.74M | -14.74M | -13.75M | -11.38M | -15.37M | -17.99M | -18.93M | -1.51K | -14.60M | 0.00 | -33.16M |
| Net Income Ratio | -1,278.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.45% | -159.47% | -7,720.98% | -4,071.92% | -199.66% | -132.89% | -127.27% | -711.72% | -579.45% | -580.55% | 0.00% | -405.98% | 0.00% | -1,540.94% |
| EPS | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -5.00 | -7.17 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| EPS Diluted | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -4.96 | -7.03 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| Weighted Avg Shares Out | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.29M | 3.08M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
| Weighted Avg Shares Out (Dil) | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.31M | 3.14M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up...
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3...
Athersys Licenses its Animal Health Assets to Ardent Animal Health
CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of...
Athersys Director Jane Wasman Appointed Board Chair
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company's recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been appointed...
Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant...
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
Why Is Athersys (ATHX) Stock Down 36% Today?
Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Athersys selling 10,937,500 shares of ATHX stock for a price of 32 cents each.
Source: https://incomestatements.info
Category: Stock Reports